KORU Medical Systems, Inc. — 10-K Summary
Issuer name in filing: Repro-Med Systems, Inc. (RMS Medical Products). The filing covers the fiscal year ended February 28, 2014, and compares it with fiscal 2013; it is not a standalone fourth-quarter report. Financial statements were audited, and the auditor issued an unqualified opinion.
Business context and reporting period
The company designs, manufactures, and markets FDA-regulated medical devices, principally the FREEDOM60 syringe infusion system and related infusion sets, RMS High-Flo subcutaneous safety needle sets, and RES-Q-VAC portable medical suction products. Infusion therapy generated 91.7% of FY2014 product sales, versus 90.0% in FY2013. The company reported 63 employees at year-end.
Financial performance and liquidity
| Metric | FY2014 | FY2013 |
|---|---|---|
| Net sales | $8.699 million | $7.764 million |
| Gross profit / gross margin | $5.310 million / 61.0% | $4.945 million / 63.7% |
| Operating profit / operating margin | $1.008 million / 11.6% | $1.062 million / 13.7% |
| Net income / net margin | $703,429 / 8.1% | $725,763 / 9.3% |
| Basic and diluted EPS | $0.02 | $0.02 |
| Cash from operations | $954,388 | $784,790 |
| Capital expenditures | $188,686 | $563,567 |
- Sales grew 12.0%; management also reported fourth-quarter sales increased $636,800, or 31.9%, year over year.
- Cash and cash equivalents were $2.227 million; certificates of deposit were $258,590. Current assets were $5.295 million against current liabilities of $771,902 (current ratio approximately 6.9).
- Accounts receivable increased to $1.745 million from $1.115 million, primarily with higher sales; inventory declined to $819,000 from $1.150 million.
- Total liabilities were $1.017 million, including $112,417 of deferred capital gain and a $155,000 deferred tax liability. Interest-bearing debt was fully repaid in May 2013; interest expense declined to $4,547 from $28,280.
Material changes versus FY2013
- Infusion product sales increased 14.9%, to $7.952 million, supported by immune globulin, antibiotics, and needle-set sales. RES-Q-VAC sales fell 5.1%, to $714,000; international growth did not offset weaker domestic demand.
- Net income declined 3.1% despite revenue growth. Cost of goods sold rose 20.2%, and gross margin fell 2.7 percentage points, reflecting product mix, higher materials and production costs, and the company’s absorption of the 2.3% medical-device excise tax.
- SG&A increased 8.7% to $3.851 million, including costs for restricted stock compensation, expanded sales and marketing, and legal work. R&D rose 47.8% to $218,150.
- Operating cash flow improved, while capital spending declined from the prior year, which included ERP and adjacent-property expenditures. The company repaid the related-party note and ended the year with no interest-bearing debt.
Outlook, risks, contingencies, and unusual items
- Management expected SCIG-related demand and sales of FREEDOM60 and High-Flo products to grow, and said it expected to meet or exceed liquidity needs for the next 12 months using operations and available capital. This is management’s expectation, not a guarantee.
- Key risks identified include reimbursement and Medicare policy changes, FDA and other regulation, competition, market acceptance and product development, access to sufficient capital, and dependence on key personnel. The company also noted uncertainty about effects of the Affordable Care Act on reimbursement.
- One distributor accounted for approximately 39.9% of FY2014 gross product revenue; $690,102 was receivable from that customer at year-end, creating customer-concentration exposure.
- Patent litigation with a competitor over needle-set claims was in early discovery; the competitor asserted counterclaims that the company considered meritless. The filing does not quantify potential financial exposure.
- The company reported absorbing the medical-device excise tax to maintain pricing. It also disclosed related-party arrangements: aircraft lease payments of $21,500 annually and a facility lease involving a director’s business; management stated lease terms were unchanged.
Important facts for investors to verify
- Whether SCIG and High-Flo demand, distributor expansion, and the reported sales momentum continued after FY2014.
- Whether customer concentration, receivable collection, and the distributor-driven sales model affected subsequent revenue, pricing, or cash conversion.
- Current Medicare reimbursement and regulatory status for the products, and any changes in reimbursement policy or medical-device taxes.
- Subsequent developments and potential costs or outcomes in the competitor litigation.
- Whether cash generation and liquidity remained adequate after debt repayment and ongoing product-development and commercialization spending.